PALI Stock Catalyst: Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with PALI-2108

Aug 6, 2025 · 7:59pm ET

Company announces positive results for novel PDE4 inhibitor

Max move

+88.1%

High of day $1.90

Sparker timei

7:59pm ET

PALI · Aug 6, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Palisade Bio, Inc. announced on 2025-08-07 Palisade Bio reported 100% clinical response in Phase 1b ulcerative colitis cohort with novel PDE4 inhibitor, PALI-2108.

The announcement cited 100%, 5/5, 62.8%, −4.0, 70%, 15%, 58%, 56%, 36%, 40%, 51%, and 95%.

PALISADE BIO, INC. has a free float of 102,195,000 shares and 149,003,000 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time PALI sparks.

Download Sniper App →

Catch the next PALI-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →